Monopar Therapeutics Inc. (MNPR)
| Market Cap | 587.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.98M |
| Shares Out | 6.70M |
| EPS (ttm) | -1.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,266 |
| Open | 87.64 |
| Previous Close | 87.63 |
| Day's Range | 85.70 - 92.26 |
| 52-Week Range | 29.18 - 105.00 |
| Beta | 1.54 |
| Analysts | Strong Buy |
| Price Target | 112.62 (+28.44%) |
| Earnings Date | Aug 11, 2026 |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MNPR stock is "Strong Buy." The 12-month stock price target is $112.62, which is an increase of 28.44% from the latest price.
News
Monopar Therapeutics announces new FoCus trial analyses
Monopar Therapeutics (MNPR) announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 will be presented at the 12th Congress of the European Academy of…
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics management to meet virtually with Piper Sandler
Virtual Meeting to be held on June 23 hosted by Piper Sandler.
Monopar Therapeutics Slides: Corporate presentation
Monopar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
Monopar Therapeutics (MNPR) announced the presentation of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver, or EASL, Congress 2026. In a presentation, the company…
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for...
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for ...
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for ...
Monopar Therapeutics Quarterly report: Q1 2026
Monopar Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Monopar Therapeutics Earnings release: Q1 2026
Monopar Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Monopar Therapeutics Proxy statement: Proxy filing
Monopar Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Monopar Therapeutics Proxy statement: Proxy filing
Monopar Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
Monopar Therapeutics (MNPR) announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 showing greater neurologic benefit versus standard of care in Wilson disease patients ...
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments fo...
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatment...
Monopar Therapeutics Earnings release: Q4 2025
Monopar Therapeutics released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
Monopar Therapeutics Annual report: Q4 2025
Monopar Therapeutics has published its Q4 2025 annual report on March 27, 2026.
Monopar Therapeutics Slides: Investor presentation
Monopar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Monopar Therapeutics appoints Susan Rodriguez as CCSO
Monopar Therapeutics (MNPR) announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead ...
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments fo...
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $115 price target The firm says ALXN1840 demonstrated “meaningful” copper mobilizati...
Monopar downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics (MNPR) to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile…
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
Cash, cash equivalents and investments as of September 30, 2025, were $143.7 million. Monopar expects that its current funds will be sufficient to continue operations at least through December 31,…
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for...
Monopar Therapeutics Earnings release: Q3 2025
Monopar Therapeutics released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.